Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERITALC vs SODIUM TETRADECYL SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
Pleurodesis for malignant pleural effusion,Pleurodesis for recurrent pneumothorax,Pleurodesis for chylothorax (off-label)
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins,Treatment of small varicose veins (off-label for larger varicose veins)
Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.
1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.
Not applicable; talc particles are not metabolized and remain in the pleural space indefinitely, with gradual clearance over months to years via macrophage uptake and lymphatic drainage.
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
Talc is an inert mineral; not metabolized. Systemic absorption may lead to deposition in tissues, but no specific metabolic pathway exists.
Not extensively metabolized; primarily eliminated unchanged by the kidneys.
Sterile talc (STERITALC) is not absorbed systemically following intrapleural administration. Excretion occurs locally via phagocytosis and clearance by pleural lymphatics; no significant renal, biliary, or fecal elimination applies.
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Not applicable; talc is an inorganic silicate, does not bind to plasma proteins.
Approximately 50% bound to plasma proteins (albumin and globulins).
Not applicable; talc remains at the site of administration (pleural space) with negligible systemic distribution.
0.2–0.3 L/kg, indicating distribution primarily within extracellular fluid and plasma volume.
Not applicable; administered via intrapleural instillation and acts locally. No systemic absorption is intended or occurs.
Intravenous: 100% (direct intravascular administration). Oral: negligible due to extensive degradation and poor absorption.
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No dose adjustment required for hepatic impairment.
Use with caution in Child-Pugh class C; no specific dose adjustment defined.
Safety and efficacy not established in pediatric patients; use not recommended.
0.1-0.3 m L of 1% solution per injection, repeated as needed; maximum 5 m L per session.
No specific dose adjustment; consider general precautions for elderly due to potential comorbidities.
No specific adjustment; use lowest effective dose due to potential increased sensitivity.
Risk of acute respiratory distress syndrome (ARDS), pneumonitis, and granulomatous inflammation secondary to talc particle absorption. Use only as a sterile, asbestos-free talc slurry or poudrage. Avoid systemic absorption.
None.
Use only sterile, asbestos-free talc,Monitor for respiratory distress, pneumothorax, or re-expansion pulmonary edema,Avoid in patients with empyema or active pleural infection,Caution in patients with compromised pulmonary function,Risk of fever, chest pain, and pleural effusion recurrence
Anaphylactic shock and severe allergic reactions have been reported.,Intra-arterial injection can cause severe necrosis or ischemia.,Extravasation may cause pain and tissue necrosis.,Use caution in patients with underlying arterial disease or hypercoagulable states.,Thromboembolic events including deep vein thrombosis and pulmonary embolism have been reported.
Hypersensitivity to talc,Pleural infection or empyema,Severe respiratory insufficiency,Pregnancy and lactation (relative contraindication),Uncontrolled bronchopleural fistula
Known hypersensitivity to sodium tetradecyl sulfate or any component of the formulation,Acute thromboembolic disease,Severe peripheral arterial disease,Valvular incompetence of the deep venous system,Uncontrolled systemic disease (e.g., diabetes, thyroid disorders),Local infection or inflammation at the injection site
No known food interactions. Maintain normal diet unless otherwise instructed by physician.
No specific food interactions have been reported with sodium tetradecyl sulfate. However, maintaining adequate hydration is recommended. Avoid excessive alcohol intake, as it may exacerbate venous insufficiency.
Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause maternal inflammation and fever, which could theoretically increase risk of preterm labor or fetal distress in third trimester. Use in pregnancy only if clearly needed.
Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack of safety data, especially in the first trimester. Theoretical risk of placental transfer is low due to high molecular weight and local administration. No reported fetal anomalies.
No data on excretion into breast milk. Due to lack of systemic absorption after pleural administration, transfer into milk is unlikely. Caution advised; consider risk-benefit.
No data on excretion into human milk. M/P ratio unknown. Due to local administration and rapid metabolism, systemic exposure is minimal. Caution advised; consider discontinuing breastfeeding or avoiding use in lactating women.
No dose adjustment necessary due to minimal systemic absorption. Use standard pleurodesis dose (typically 2-5 g as slurry or poudrage).
No specific dose adjustments recommended. Use only if clearly needed, with smallest effective volume and concentration. Physiological changes in pregnancy (increased plasma volume, altered coagulation) may affect response but no pharmacokinetic data exist.
STERITALC (talc) is used for pleurodesis in malignant pleural effusion or recurrent pneumothorax. Administer via chest tube as a slurry or poudrage. Monitor for chest pain, fever, and hypoxia post-instillation. Ensure lung re-expansion before use to avoid trapped lung. Do not use in patients with empyema or bronchopleural fistula.
Sodium tetradecyl sulfate is a sclerosing agent used for the treatment of varicose veins and telangiectasias. It works by causing endothelial damage and subsequent fibrosis of the vein. Use with caution in patients with a history of deep vein thrombosis, pulmonary embolism, or hypercoagulable states. Allergic reactions, including anaphylaxis, have been reported; a test dose is recommended. Avoid extravasation as it may cause tissue necrosis. Compression stockings should be applied post-injection to enhance efficacy and reduce complications.
You may experience chest pain, fever, or shortness of breath after the procedure.,The medication causes the layers of your lung to stick together to prevent fluid or air buildup.,Report any severe pain, difficulty breathing, or signs of infection immediately.,Avoid strenuous activity and keep the chest tube site clean and dry.,Follow up with your doctor for imaging to confirm pleurodesis effectiveness.
This medication is injected directly into your varicose veins to cause them to scar and close.,You may experience temporary bruising, pain, or redness at the injection site.,It is normal for the treated veins to feel hard and lumpy for a few weeks after treatment.,You will need to wear compression stockings for several days to weeks as directed by your healthcare provider.,Avoid sun exposure to the treated area until bruising resolves to reduce the risk of hyperpigmentation.,Seek immediate medical attention if you experience signs of an allergic reaction, chest pain, or difficulty breathing.,Do not discontinue prescribed blood thinners unless instructed by your doctor, as the risk of bleeding may be increased.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERITALC vs SODIUM TETRADECYL SULFATE, answered by our medical review team.
STERITALC is a Sclerosing Agent that works by Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.. SODIUM TETRADECYL SULFATE is a Sclerosing Agent that works by Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERITALC and SODIUM TETRADECYL SULFATE depend on the specific clinical indication. These are both Sclerosing Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERITALC is: Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.. The standard adult dose of SODIUM TETRADECYL SULFATE is: 1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERITALC and SODIUM TETRADECYL SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERITALC is classified as Category C. Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause mat. SODIUM TETRADECYL SULFATE is classified as Category C. Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.